PD-L1 expression also serves as a prognostic marker, often associated with more aggressive tumors, and anti-PD-1/PD-L1 therapies have significantly improved outcomes in cancers such as melanoma (Patel and Kurzrock 2015, Yamaguchi et al. 2022). This evidence concerns the gene CD274 and melanoma.